From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Biotin-4-aminophenol is a biotin-phenol analog. Biotin-4-aminophenol generates free radicals and conjugates to tyrosine residues in proteins more efficiently and selectively than the previously reported BP1[1].
mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates [1].
SR-4133 is a potent and highly CK1ε selective inhibitor with an IC50 of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1[1].
Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of 4E-BP1 and p27 Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer [1].
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) [1].
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner [1].
IGF2BP1-IN-1 (Compound A11) is a IGF2BP1 inhibitor and inhibits downstream signaling. IGF2BP1-IN-1 binds to IGF2BP1 protein with a KD value of 2.88 nM. IGF2BP1-IN-1 inhibits cancer cells proliferation (IC50: 9 nM for A549 cell, 34 nM for HCT116). IGF2BP1-IN-1 induces cancer cell apoptosis. GF2BP1-IN-1 inhibits tumor growth in A549 xenograft mouse model [1].
IGF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IGF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
MIS18BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for MIS18BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
IRF2BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for IRF2BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ITGB1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ITGB1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
G3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for G3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
N4BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for N4BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH3BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH3BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TAX1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAX1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TNKS1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
TP53BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TP53BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
UNC3474 is a small molecule ligand, binding with 53BP1. UNC3474 binds the aromatic methyl-lysine binding cage of 53BP1TT, with a dissociation constant (Kd) of 1.0 ± 0.3 μM. UNC3474 inhibits the recruitment of 53BP1 to DSBs by stabilizing a pre-existing autoinhibited state of 53BP1 in cells [1].
FAZ-3532 (compound G3Ia) is an inhibitor of binding to the NTF2L domain of G3BP1/2 that binds to G3BP1 with a Kd of 0.54 μM. FAZ-3532 targets the protein-protein interaction domain of G3BP1/2 and specifically inhibits co-condensation of G3BP1, caprin 1, and RNA in vitro [1].
FAZ-3780 (compound G3Ib) is an inhibitor of binding to the NTF2L domain of G3BP1/2 that binds to G3BP1 with a Kd of 0.15 μM. FAZ-3780 targets the protein-protein interaction domain of G3BP1/2 and specifically inhibits co-condensation of G3BP1, caprin 1, and RNA in vitro [1].
AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 to inhibit the migration of H1299 cells with high endogenous IGF2BP1 expression. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation [1].
UNC9512 is a potent methyl-lysine reader p53 binding protein 1(53BP1) antagonist. UNC9512 can be used to study the role of 53BP1 in DNA repair, gene editing and tumorigenesis [1].
UNC-2170 is a functionally active, fragment-like ligand for 53BP1 (IC50=29 µM; Kd=22 µM). UNC-2170 shows at least 17-fold selectivity for 53BP1 as compared to nine other methyl-lysine (Kme) reader proteins. 53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) pathways and is recruited to sites of double-strand breaks (DSB) [1].
Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
Ranolazine-d8 (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].
Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Tat-peptide 190-208 TFA is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 TFA increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 TFA likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 TFA can be used for ischemic protection during endovascular repair for intracranial aneurysms [1].
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron [1].
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron [1].
Tat-peptide 190-208 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 can be used for ischemic protection during endovascular repair for intracranial aneurysms [1].
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner [1].
CD42b/GP1BA protein is an important platelet membrane protein that interacts with the A1 domain of von Willebrand factor and contributes to the formation of subendothelial platelet plugs. Its GP1BA subunit forms a disulfide-linked complex with two GP1BB subunits, collectively called GP-Ib. CD42b/GP1BA Protein, Human (515a.a, HEK293, His) is the recombinant human-derived CD42b/GP1BA protein, expressed by HEK293 , with C-His labeled tag. The total length of CD42b/GP1BA Protein, Human (515a.a, HEK293, His) is 515 a.a., with molecular weight of 100-130 kDa.
The ACO1 protein is a bifunctional iron sensor that dynamically adapts to cellular iron levels. Under conditions of iron deficiency, it is converted to mRNA binding and regulates iron-related gene expression. Aconitase 1/ACO1 Protein, Human (sf9, His) is the recombinant human-derived Aconitase 1/ACO1 protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of Aconitase 1/ACO1 Protein, Human (sf9, His) is 889 a.a., with molecular weight of ~90 kDa.
Syntaxin-BP1 Protein crucially regulates synaptic vesicle docking and fusion, binding GTP-binding proteins and ensuring efficient neurotransmission. It interacts with syntaxin in a 1:1 ratio, displaying specificity for syntaxins 1, 2, and 3 (excluding syntaxin 4). Syntaxin-BP1 actively engages in neurotransmitter release by interacting with STX1A, facilitating SNARE complex assembly, recruiting SNAP25 and VAMP2, and mediating neurotransmitter release. It also controls alpha-synuclein/SNCA aggregation and promotes RAB3A dissociation from vesicle membranes, highlighting its multifaceted role in synaptic processes and diverse molecular interactions. Syntaxin-BP1 Protein, Human (sf9, His-GST) is the recombinant human-derived Syntaxin-BP1 protein, expressed by Sf9 insect cells, with N-His, N-GST labeled tag. The total length of Syntaxin-BP1 Protein, Human (sf9, His-GST) is 594 a.a., with molecular weight of ~80 kDa.
Siglec-6 Protein, a putative adhesion molecule, facilitates sialic acid-dependent binding to cells, specifically binding to alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. Siglec-6 interacts with LEP. Siglec-6 Protein, Human (HEK293, Fc) is the recombinant human-derived Siglec-6 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Siglec-6 Protein, Human (HEK293, Fc) is 305 a.a., with molecular weight of 70-90 kDa.
Siglec-6 Protein, a putative adhesion molecule, facilitates sialic acid-dependent binding to cells, specifically binding to alpha-2,6-linked sialic acid. Its sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. Siglec-6 interacts with LEP. Siglec-6 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Siglec-6 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Siglec-6 Protein, Human (HEK293, His-Avi) is 305 a.a., with molecular weight of 55-70 kDa.
rHuEukaryotic translation initiation factor 4E-binding protein 1/EIF4EBP1, His; Eukaryotic Translation Initiation Factor 4E-Binding Protein 1; 4E-BP1; eIF4E-Binding Protein 1; Phosphorylated Heat- and Acid-Stable Protein Regulated by Insulin 1; PHAS-I; EIF4EBP1
EIF4EBP1 is a translation initiation repressor protein that complexly regulates EIF4E activity. In the hypophosphorylated state, EIF4EBP1 competes with EIF4G1/EIF4G3 to inhibit translation by binding to EIF4E. EIF4EBP1 Protein, Human (His) is the recombinant human-derived EIF4EBP1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of EIF4EBP1 Protein, Human (His) is 118 a.a., with molecular weight of ~17.0 kDa.
Ranolazine-d8 (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].
Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, IHC-P, IP
Human, Mouse, Rat, Hamster
4E BP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 13 kDa, targeting to 4E BP1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.
EIF4EBP1; Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, IHC-P, IP
Human, Mouse, Rat
Phospho-4E BP1 (Thr46) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 13 kDa, targeting to Phospho-4E BP1 (Thr46). It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.
53BP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 214 kDa, targeting to TP53BP1. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.
